Effects of simvastatin plus amlodipine and telmisartan in treatment of hypertension and left ventricular hypertrophy

AIM: To compare the effect of amlodipine plus telmisartan and simvastatin plus amlodipine and telmisartan on blood pressure in patients with hypertension and left ventricular hypertrophy (LVH) and to explore the effect of simvastatin on LVH. METHODS: Seventy-nine cases of diagnosed LVH were randomly assigned to amlodipine+amiloride group (59 cases) and amlodipine+telmisartan+simvastatin group (20 cases). Eighteen months after treatment, cardiac morphology and function and blood pressure changes were observed in patients. RESULTS: After treatment, systolic blood pressure (SBP), diastolic blood pressure (DBP), interventricular septal thickness (IVST), left ventricular mass (LVM) and left ventricular mass index (LVMI) significantly decreased in both amlodipine+telmisartan group and amlodipine+telmisartan+simvastatin group (P<0.01). E/A ratio and EF values were significantly improved (P<0.01). After treatment, no significant difference was observed in SBP and DBP between groups (P>0.05). A significant difference was found in IVST, LVPWT, LVM and LVMI (P<0.05) between groups and the effect of amlodipine+telmisartan+simvastatin was more obvious. CONCLUSION: Compared with amlodipine plus telmisartan, combined administration of amlodipine+telmisartan+simvastatin is more effective in treating hypertension and reversing LVH, suggesting that simvastatin has the synergistic effect of reversing LVH and conferring cardiac protection.